IMV (IMV) Receives a Hold from B.Riley FBR

By Ryan Adsit

In a report released today, Mayank Mamtani from B.Riley FBR maintained a Hold rating on IMV (IMVResearch Report), with a price target of $3.00. The company’s shares closed last Monday at $2.89.

According to TipRanks.com, Mamtani is a 5-star analyst with an average return of 14.2% and a 46.1% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals, Arrowhead Pharmaceuticals, and Spectrum Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for IMV with a $6.19 average price target, representing a 108.4% upside. In a report issued on May 22, Raymond James also maintained a Hold rating on the stock with a C$3.00 price target.

See today’s analyst top recommended stocks >>

Based on IMV’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $68K and GAAP net loss of $9.66 million. In comparison, last year the company earned revenue of $82K and had a GAAP net loss of $5.94 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

IMV, Inc. is a clinical-stage biopharmaceutical company pioneering a new class of immunotherapy in Oncology. Its proprietary drug delivery platform (DPX) enables the programming of immune cells in vivo. The firm’s candidate, DPX-Survivac, is a T cell-activating immunotherapy combining DPX with a specific tumor target: Survivin. DPX-Survivac is in clinical evaluation as a monotherapy in advanced ovarian cancer and in combination with Merck’s Keytruda across multiple cancer indications. The company was founded by Warwick Kimmins and Brian E. Lowe on March 28, 2000 and is headquartered in Dartmouth, Canada.